AURKA and neuroblastoma: Small molecule inhibitors of AURKA, such as MLN8054 and MLN8237 (Alisertib), have been described to reduce MYCN stability by increased degradation, to increase survival in an in vivo model of neuroblastoma [204], and to reduce neuroblastoma-induced endothelial cell proliferation [205].